Skip to main content Accessibility help

The Harms of Enhancement and the Conclusive Reasons View



Many critics of bioenhancement go to considerable lengths to establish the existence of reasons against pursuing bioenhancements but do little to establish the absence of reasons in favor. This suggests that they accept what Allen Buchanan has called the conclusive reasons view (CRV). According to this view, our reasons against bioenhancement are obviously decisive, so there is no need to balance them against countervailing reasons. Buchanan criticizes the CRV by showing that the reasons most commonly adduced against bioenhancement are not decisive, or, at least, not obviously so.

In this article, I suggest that both Buchanan and the authors to whom he is responding underestimate the strength of the case for the CRV. There are, I argue, harm-based reasons against bioenhancement that provide stronger support to the CRV than the reasons that have most often been adduced by critics of enhancement. However, I then argue that even these harm-based reasons are not obviously decisive. Thus, I ultimately agree with Buchanan about the falsity of the CRV, though I disagree with him about the reasons for its falsity.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The Harms of Enhancement and the Conclusive Reasons View
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      The Harms of Enhancement and the Conclusive Reasons View
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      The Harms of Enhancement and the Conclusive Reasons View
      Available formats


This is an Open Access article, distributed under the terms of the Creative Commons Attribution license (, which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.


Hide All


1. Buchanan, AE. Enhancement and the ethics of development. Kennedy Institute of Ethics Journal 2008;18(1):134.

2. Buchanan, AE. Beyond Humanity? The Ethics of Biomedical Enhancement. Oxford: Oxford University Press; 2011.

3. Buchanan, AE. Better Than Human: The Promise and Perils of Enhancing Ourselves. New York: Oxford University Press; 2011.

4. See note 2, Buchanan 2011, at 16.

5. See, for example, Fukuyama, F. Our Posthuman Future: Consequences of the Biotechnology Revolution. New York: Profile Books; 2002.

6. Fukuyama, F. Transhumanism. Foreign Policy 2004;144:42–3.

7. Kass, LR. Life, Liberty, and the Defense of Dignity. San Francisco: Encounter Books; 2002.

8. Kass, LR. Ageless bodies, happy souls. The New Atlantis 2003;1:928.

9. Sandel, M. The Case against Perfection: Ethics in the Age of Genetic Engineering. Cambridge, MA: Harvard University Press; 2007.

10. See note 9, Sandel 2007, at 92, 95.

11. See note 5, Fukuyama 2002, at 172.

12. See note 9, Sandel 2007, at 5–24.

13. See note 1, Buchanan 2008, and note 2, Buchanan 2011.

14. See note 1, Buchanan 2008, at 19–20.

15. See note 1, Buchanan 2008.

16. It is true that Michael Sandel, the chief exponent of the concern about expressing objectionable attitudes, connects this concern with a concern about the undermining of social solidarity, which might be thought to be ultimately a concern about harm to others (see note 9, Sandel 2007, at 89–92). However, I am inclined to think that he conflates two distinct arguments here. Taken at face value, the concern about expressing objectionable attitudes is not a consequence-based concern; it is a concern about motives. By contrast, the concern about undermining social solidarity plainly is a concern about the possible consequences of biomedical enhancement. It is, of course, possible that the motives to which Sandel objects would causally contribute to the undermining of social solidarity. In that case, the appeal to objectionable attitudes could be understood as a disguised appeal to a consequence-based concern. However, there is little reason to interpret Sandel’s objection in this way: he does not provide any argument for such a causal connection, and he is elsewhere at pains to emphasize that his appeal to objectionable attitudes is not a consequence-based concern (e.g., at 95–96). This leads me to conclude that Sandel’s appeal to the undermining of social solidarity is distinct from his main, attitudes-based critique of enhancement. I consider an argument similar to his solidarity-based critique later in this article.

17. Michael Sandel suggests that standard liberal principles are unable to capture the problematic nature of bioenhancement and takes this to count not in favor of bioenhancement but against liberalism. See note 9, Sandel 2007, at chap. 1.

18. Caldwell, JA, Caldwell, JL. Fatigue in military aviation: An overview of U.S. military-approved pharmacological countermeasures. Aviation, Space, and Environmental Medicine 2005;76(1 Suppl):C39C51.

19. Academy of Medical Sciences. Brain Science, Addiction and Drugs. London: Academy of Medical Sciences; 2008, at 158–9.

20. Chatterjee, A. A medical view of potential adverse effects. Nature 2009;457(7229):532–3.

21. McKibben B. Designer genes. Orion 2003 Apr 30; available at (last accessed 15 Sep 2014).

22. President’s Council on Bioethics. Beyond Therapy: Biotechnology and the Pursuit of Happiness. Washington, DC: President’s Council on Bioethics; 2003, at 131–4, 280–1.

23. See note 22, President’s Council 2003, at 135–7, 283–5.

24. Farah, MJ, Illes, J, Cook-Deegan, R, Gardner, H, Kandel, E, King, P, et al. Neurocognitive enhancement: What can we do and what should we do? Nature Reviews Neuroscience 2004;5(5):421–5.

25. British Medical Association. Boosting Your Brain Power: Ethical Aspects of Cognitive Enhancements. London: British Medical Association; 2007, at 1923.

26. See note 9, Sandel 2007, at 18–19.

27. For example, the Elementary Education Act of 1870, which paved the way to compulsory primary education in England and Wales, was motivated largely by a concern for those countries to maintain their international economic competitiveness. See Ramirez, FO, Boli, J. The political construction of mass schooling: European origins and worldwide institutionalization. Sociology of Education 1987;60(1):217.

28. See note 9, Sandel 2007, at 89–91.

29. Wikler DI. Paternalism in the age of cognitive enhancement: Do civil liberties presuppose roughly equal mental ability. In: Savulescu J, Bostrom N, eds. Oxford: Oxford University Press; 2009;341–55.

30. Wilson, J. Transhumanism and moral equality. Bioethics 2007;21(8):419–25.

31. Buchanan, A. Moral status and human enhancement. Philosophy & Public Affairs 2009;37(4):346–81.

32. See note 2, Buchanan 2011.

33. Douglas, T. Human enhancement and supra-personal moral status. Philosophical Studies 2013;162(3):473–97.

34. DeGrazia, D. Genetic enhancement, post-persons and moral status: A reply to Buchanan. Journal of Medical Ethics 2012;38(3):135–9.

35. Agar, N. Why is it possible to enhance moral status and why doing so is wrong? Journal of Medical Ethics 2013;39(2):6774.

36. This example is modified from Wikler 2009 (see note 29) and Buchanan 2009 (see note 31).

37. See note 1, Buchanan 2008, and note 2, Buchanan 2011, at 35–67.

38. Bostrom, N, Ord, T. The reversal test: Eliminating status quo bias in applied ethics. Ethics 2006;116(4):669–70.

39. See also note 2, Buchanan 2011, at 38–49, though compare Persson, I, Savulescu, J. Unfit for the Future: The Need for Moral Enhancement. Oxford: Oxford University Press; 2012.

40. Sunstein, CR. Laws of Fear: Beyond the Precautionary Principle. Cambridge: Cambridge University Press; 2005, at 18.

41. United Nations Environment Programme. Rio Declaration on Environment and Development. Nairobi: United Nations Environment Programme; 1992, principle 15.

42. Ashford N, Barrett K, Bernstein A, Constanza R, Costner P, Cranor C, et al. Wingspread Statement on the Precautionary Principle; 1998; available at (last accessed 15 Sep 2014).

43. See, for a similar formulation of the precautionary principle, Seas at Risk. Final Declaration of the First European “Seas at Risk” Conference (Copenhagen, 26–28 October 1994): A Shadow Declaration. Brussels: Seas at Risk; 1994, at 28: “If the ‘worst case scenario’ for a certain activity is serious enough then even a small amount of doubt as to the safety of that activity is sufficient to stop it taking place.”

44. Manson, NA. Formulating the precautionary principle. Environmental Ethics 2002;24:263–74.

45. See note 40, Sunstein 2005, at 4, 18–49.

46. See, for example, Nagel, T. Justice and nature. Oxford Journal of Legal Studies 1997;17(2):303–21, at 315.

47. For discussion of the ways in which biological interventions might influence the moral status of our conduct, see Douglas, T. Enhancing moral conformity and enhancing moral worth. Neuroethics 2014; 7: 7591.

48. See, for a recent review, Thibaut, F, Barra, FDL, Gordon, H, Cosyns, P, Bradford, JMW. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World Journal of Biological Psychiatry 2010;11(4):604–55.

49. Bond, AJ. Antidepressant treatments and human aggression. European Journal of Pharmacology 2005;526(13):218–25.

50. Khanzode, L, Saxena, K, Kraemer, H, Chang, K, Steiner, H. Efficacy profiles of psychopharmacology: Divalproex sodium in conduct disorder. Child Psychiatry & Human Development 2006;37(1):5564.

51. Danziger, S, Levav, J, Avnaim-Pesso, L. Extraneous factors in judicial decisions. Proceedings of the National Academy of Sciences 2011;108(17):6889–92.

52. For discussion of various ways in which existing drugs may influence morally significant conduct, see Levy N, Douglas T, Kahane G, Terbeck S, Cowen P, Hewstone M, Savulescu J, Are you morally modified? The moral effects of widely used pharmaceuticals. Philosophy, Psychiatry and Psychology; Forthcoming.

53. Crockett, MJ, Apergis-Schoute, A, Herrmann, B, Lieberman, MD, Müller, U, Robbins, TW, et al. Serotonin modulates striatal responses to fairness and retaliation in humans. Journal of Neuroscience 2013;33(8):3505–13.

54. De Jongh, R, Bolt, I, Schermer, M, Olivier, B. Botox for the brain: Enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neuroscience & Biobehavioral Reviews 2008;32(4):760–76.

I would like to thank an audience at the University of Manchester and an anonymous reviewer for the Cambridge Quarterly of Healthcare Ethics for comments on an earlier draft of this article. I thank the Wellcome Trust (grant numbers 100705/Z/12/Z, WT087211 and GR077879AIA) for their funding.


The Harms of Enhancement and the Conclusive Reasons View



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed